While Hydroxychloroquine showed some early indications that it may be helpful as a therapy to treat COVID-19 – recent trial results suggest that it’s probably a dead end.A French study this weekshowed that the drug is not clinically efficient for use of patients with COVID-19. The study retroactively looked at the medical records of 181 patients diagnosed with COVID-19 and whom developed pneumonia and required oxygen.
Forty-eight hours after being admitted, 84 patients were given Hydroxychloroquine and doctors found that there was no statistically significant difference in death rates. A side effect of taking of the drug is abnormal heart rhythms.
While a small study, it shows that this drug may not be suitable to use on COVID-19 patients. Additional studies are needed with larger sample sizes. This study has not been peer-reviewed and does not state how long patients remained in the hospital or have symptoms after taking the drug.
